Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get.
Posted by rob on October 31, 2009 under Uncategorized | 
Comments are off for this article
| Related Articles |
Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get.
Hum Vaccin. 2009 Nov 23;5(11)
Authors: di Pietro A, Tosti G, Ferrucci PF, Testori A
Heat shock proteins (HSPs) are highly conserved, stress-induced proteins and function as chaperones stabilizing and delivering peptides. In several preclinical studies, tumor derived HSP-peptide complexes (HSPPCs) has been shown to be able to induce immunity against several malignancies. HSP-based vaccines, indeed, work across tumor types, bypassing the need for the identification of the single immunogenic peptide, and thus emerging as a class of tumor- and patient-specific vaccines. HSPPC-96-based vaccine vitespen((R)) (formerly Oncophage((R))) is the first autologous cancer vaccine made from individual patients’ tumors which not only confirmed its activity in different malignancies (e.g., gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin’s lymphoma and chronic myelogenous leukemia), but was also successfully tested in phase III clinical trials in melanoma and kidney cancer. Even more HSPPC-96-based vaccine demonstrated an excellent safety profile, with almost no toxicity. HSP-based vaccines are emerging as a novel therapeutic approach with a suggestive role in cancer therapy.
PMID: 19875926 [PubMed - as supplied by publisher]